checkmate-722: investigating the addition of immunotherapy to chemotherapy in egfr-mutant nsclc
Published 1 year ago • 277 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
3:44
immunotherapy as combination and neoadjuvant therapies in nsclc
-
1:31
impower150: efficacy outcomes of atezolizumab addition in pre-treated egfr-mutated nsclc
-
2:33
checkmate 227: chemo-free nsclc treatment
-
4:07
chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
-
1:33
neoadjuvant egfr tki trials in nsclc
-
2:54
pembrolizumab or egfr tyrosine kinase inhibitors in nsclc?
-
6:04
checkmate 816 trial: nivolumab platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
3:08
choosing immunotherapy as front line therapy for non-actionable nsclc
-
2:36
atezolizumab with erlotinib in combination treatment for egfr mutant nsclc
-
1:22
dr. bauml on the use of immunotherapy in oligometastatic nsclc
-
1:36
quality of life and symptom control for non-squamous nsclc patients on nivolumab (checkmate 057)
-
2:20
selecting patients with nsclc who benefit from immunotherapy or targeted therapies
-
7:23
surgical outcomes from checkmate 816: nivo plus chemo vs chemo alone as neoadjuvant treatment fo...
-
2:54
considerations for duration and de-escalation of immunotherapy in lung cancer
-
3:30
checkmate 9la: tmb and immune checkpoint inhibitor efficacy
-
6:26
selecting patients for immunotherapy based on driver mutations
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
5:51
checkmate-227 and the role of tmb in nsclc